CNS Disorders  >>  Intuniv (guanfacine XR)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Intuniv (guanfacine XR) / Shionogi, Takeda
NCT04866030: Drug Use Study With Intuniv® in Australia

Completed
N/A
100
RoW
Shire
Attention Deficit Hyperactivity Disorder (ADHD)
08/21
08/21
NCT02259517: An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

Terminated
N/A
38
US
Guanfacine, Intuniv, GXR, Lisdexamfetamine, Vyvanse, LDX
New York State Psychiatric Institute, Columbia University, American Academy of Child Adolescent Psychiatry., Shire
Attention Deficit Hyperactivity Disorder
11/21
11/21
NCT05870605: Drug Use Study With Intuniv® in European Countries

Completed
N/A
5000
Europe
No Intervention
Shire
Attention Deficit Hyperactivity Disorder (ADHD)
04/22
04/22
AGUALIS, NCT03333668: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents

Active, not recruiting
N/A
20
Europe
Lisdexamfetamine dimesylate, Vyvanse (Shire Pharmaceuticals Ltd.), Guanfacine Extended Release Oral Tablet, Intuniv (Shire Pharmaceuticals Ltd.), Placebo
King's College London, Shire
ADHD
12/22
03/25

Download Options